Tofogliflozin

Tofogliflozin (CSG-452) is a highly efficient and selective inhibitor of SGLT2, with Ki values of 2.9, 14.9 and 6.4nM for human, rat and mouse SGLT2 respectively.

Product Specifications

CAS Number

[903565-83-3]

Product Name Alternative

CSG452

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

SGLT

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/Tofogliflozin.html

Purity

98.38

Solubility

10 mM in DMSO

Smiles

O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@]21OCC3=CC=C(CC4=CC=C(CC)C=C4)C=C23

Molecular Formula

C22H26O6

Molecular Weight

386.44

Precautions

H302, H315, H319, H335

References & Citations

[1]Nagata T, et al. Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice. Br J Pharmacol. 2013 Oct;170 (3) :519-31.|[2]Yamane M, et al. In vitro profiling of the metabolism and drug-drug interaction of tofogliflozin, a potent and highly specific sodium-glucose co-transporter 2 inhibitor, using human liver microsomes, human hepatocytes, and recombinant human CYP. Xenobiotica. 2014 Oct 28:1-9.|[3]Suzuki M, et al. Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice. J Pharmacol Exp Ther. 2012 Jun;341 (3) :692-701.|[4]Nagata T, et al. Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats. Am J Physiol Endocrinol Metab. 2013 Feb 15;304 (4) :E414-23.

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, protect from light)

Scientific Category

Reference compound1

Clinical Information

Launched

Isoform

SGLT2

Citation 01

Biochem Pharmacol. 2016 Feb 1:101:27-39.|J Chromatogr B Analyt Technol Biomed Life Sci. 2020 Mar 15;1141:122020.|Biochem Pharmacol. 2018 Jun:152:45-59.|University of Paris. 2022 Sep 19.